Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Queensland Health
US Department of Justice
Daiichi Sankyo
Medtronic
QuintilesIMS
Moodys
US Army
Argus Health
Farmers Insurance

Generated: October 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,329,159

« Back to Dashboard

Which drugs does patent 8,329,159 protect, and when does it expire?


Patent 8,329,159 protects DAKLINZA and is included in one NDA.

This patent has forty-seven patent family members in thirty-one countries.

Summary for Patent: 8,329,159

Title:Hepatitis C virus inhibitors
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Inventor(s): Belema; Makonen (North Haven, CT), Nguyen; Van N. (New Britain, CT)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:11/835,462
Patent Claim Types:
see list of patent claims
Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bristol-myers Squibb
DAKLINZA
daclatasvir dihydrochloride
TABLET;ORAL206843-001Jul 24, 2015RXYesNo► Subscribe► SubscribeY
Bristol-myers Squibb
DAKLINZA
daclatasvir dihydrochloride
TABLET;ORAL206843-002Jul 24, 2015RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,329,159

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,900,566Hepatitis C virus inhibitors► Subscribe
8,303,944Hepatitis C virus inhibitors► Subscribe
9,758,487Hepatitis C virus inhibitors► Subscribe
8,642,025Hepatitis C virus inhibitors► Subscribe
8,846,023Hepatitis C virus inhibitors► Subscribe
9,227,961Hepatitis C virus inhibitors► Subscribe
8,574,563Hepatitis C virus inhibitors► Subscribe
9,421,192Hepatitis C virus inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,329,159

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina063684► Subscribe
Australia2007286222► Subscribe
BrazilPI0716483► Subscribe
Canada2660520► Subscribe
Chile2007002327► Subscribe
China101558059► Subscribe
China104447707► Subscribe
Colombia6150171► Subscribe
Cyprus1115594► Subscribe
Cyprus1117641► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Mallinckrodt
Dow
Harvard Business School
Federal Trade Commission
Argus Health
Cipla
Merck
Colorcon
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot